Effect of Folic Acid Adminsteration on Plasma Homocysteine Level in Preeclampsaia among Egyptian Population
Medical & Clinical Research · 2015
DOI: 10.33140/mcr.01.01.03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical & Clinical Research, 2015. Die Arbeit nennt 130 Literaturangaben.
Abstract (Originalsprache)
Background
Hyperhomocysteinemia (HHC) appears to cause endothelial dysfunction through direct toxic and oxidative stress mechanisms. HHC was found to be seven times more common in women with history of severe preeclampsia.
Objective
The aim of this study was to determine the effect of folic acid administration on the maternal serum homocysteine level in mild and severe pre-eclamptic cases between 28 and 32 weeks of gestation.
Setting
The study was conducted on forty pre-eclamptic patients recruited from Elshatby Maternity University Hospital, Alexandria, Egypt over year 2012. Study design: The cases were subdivided into two groups; 20 mild and 20 severe pre-eclamptic cases. Each group was subdivided into two subgroups • Ten cases will take folic acid 5mg daily from 28 to 32 weeks. • Ten control cases (no folic acid administration).
Results
The present study found that plasma homocysteine level was lowered after folic acid administration for both mild and severe cases. In the control group who did not receive folic acid, they had high homocysteine level .
Conclusion
Folic acid can be administrated till the second trimester of pregnancy to decrease the risk of preeclampsia.
Zitieren
APA
(2015). Effect of Folic Acid Adminsteration on Plasma Homocysteine Level in Preeclampsaia among Egyptian Population. Medical & Clinical Research. https://doi.org/10.33140/mcr.01.01.03
Vancouver
Effect of Folic Acid Adminsteration on Plasma Homocysteine Level in Preeclampsaia among Egyptian Population. Medical & Clinical Research. 2015. doi:10.33140/mcr.01.01.03
BibTeX
@article{euvimed2015,
title = {Effect of Folic Acid Adminsteration on Plasma Homocysteine Level in Preeclampsaia among Egyptian Population},
journal = {Medical & Clinical Research},
year = {2015},
doi = {10.33140/mcr.01.01.03}
}
EUVIMED